| The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved a wide variety of safe and effective new drug therapies in 2021 despite challenges brought on by the ongoing COVID-19 pandemic. These new approvals, spanning a wide range of diseases and conditions, aim to help many patients live better and potentially longer lives. In 2021, we approved 50 new drugs never before approved or marketed in the U.S., known as "novel" drugs. We also approved drugs in new capacities, such as for new uses and patient populations. The 2021 approvals target diseases and conditions such as: - Heart, blood, kidney, and endocrine diseases, including treatments for diabetes, chronic kidney disease, and chronic weight management.
- Autoimmune, inflammatory and lung diseases, such as inflammatory bowel disease and cystic fibrosis.
- Neurological conditions, such as Alzheimer's disease, opioid overdose, and migraine.
- Infectious diseases, including HIV-1, smallpox, and cytomegalovirus infection.
- Different types of cancers, such as lung cancer, basal cell carcinoma, kidney cancer, breast cancer and stomach cancer.
| | | |
No comments:
Post a Comment